Cargando…

Correction: Chronic immune checkpoint inhibitor pneumonitis

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668375/ https://www.ncbi.nlm.nih.gov/pubmed/33188039 http://dx.doi.org/10.1136/jitc-2020-000840corr1

Ejemplares similares

Chronic immune checkpoint inhibitor pneumonitis
por: Naidoo, Jarushka, et al.
Publicado: (2020)

Correction: Efficacy of immune checkpoint inhibitors for in-transit melanoma
Publicado: (2020)

Correction: Immune checkpoint inhibitor-associated celiac disease
Publicado: (2020)

Correction: Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis
por: Reddy, Haritha G., et al.
Publicado: (2018)

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
por: Lin, Xinqing, et al.
Publicado: (2022)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
por: Wang, Hanping, et al.
Publicado: (2019)

Correction: Acute kidney injury in patients treated with immune checkpoint inhibitors
Publicado: (2023)

Correction: Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Publicado: (2022)

Correction: Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
Publicado: (2021)

HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis
por: Correale, Pierpaolo, et al.
Publicado: (2020)

Long-term outcomes in patients with immune checkpoint inhibitor induced pneumonitis
por: Davis Puente, Andrea, et al.
Publicado: (2023)

Identification and prediction of immune checkpoint inhibitors-related pneumonitis by machine learning
por: Gong, Li, et al.
Publicado: (2023)

Publisher Correction: Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma
por: Beug, Shawn T., et al.
Publicado: (2018)

Correction: On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19
Publicado: (2021)

Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation
por: Zhu, Shicong, et al.
Publicado: (2020)

Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies
por: Chen, Xuguang, et al.
Publicado: (2021)

Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis
por: Ando, Hiroyuki, et al.
Publicado: (2021)

The Many Faces of Immune Checkpoint Inhibitor-Associated Pneumonitis: 4 Case Reports
por: Mojsak, Damian, et al.
Publicado: (2022)

Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor
por: Wang, Wenxian, et al.
Publicado: (2022)

Correction: (68)Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis
Publicado: (2022)

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
por: Reuss, Joshua E., et al.
Publicado: (2021)

Correction to: Organ Dysfunction in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
Publicado: (2022)

Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer
por: Lu, Xiaotong, et al.
Publicado: (2022)

Correction to: Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2019)

Correction: Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis
Publicado: (2021)

Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment
por: Rossi, Ernesto, et al.
Publicado: (2020)

Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors
por: Uchida, Yasuki, et al.
Publicado: (2022)

Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer
por: Tan, Peixin, et al.
Publicado: (2023)

Radiation recall pneumonitis from immune checkpoint inhibitors after extra pulmonary radiation
por: Kao, Leslie E., et al.
Publicado: (2023)

Correction: T lymphocyte-targeted immune checkpoint modulation in glioma
Publicado: (2020)

Correction: Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer
Publicado: (2021)

Correction: Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach
Publicado: (2021)

Correction to: Diagnostic Value of the International Society of Cardio‐Oncology Definition for Suspected Immune Checkpoint Inhibitor–Associated Myocarditis
Publicado: (2023)

Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis
por: Chen, Xinru, et al.
Publicado: (2020)

Correction: On the mechanism of anti-CD39 immune checkpoint therapy
Publicado: (2020)

Correction: MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy
Publicado: (2020)

Correction: Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept
Publicado: (2022)

Correction to: Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors
por: von Itzstein, Mitchell S., et al.
Publicado: (2022)

Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis
por: Gatti-Mays, Margaret, et al.
Publicado: (2021)

Dosimetric Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors
por: Bi, Jianping, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2rr4a7372s6fd4a4r2tke2c7nn